There is a need for options to address progressed liver cancer after the treatment of immune checkpoint inhibitors (ICIs). Sintilimab and lenvatinib are active as monotherapies liver cancer; Therefore, our aim was to evaluate the efficacy of lenvatinib combined with sintilimab in the treatment of these patients.
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus Sintilimab in patients with advanced liver cancer progressed after treatment with immune checkpoint inhibitors.